Small Molecule Therapeutics for Treating Metachromatic Leukodystrophy

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes new small molecule compounds, specifically sulfatase inhibitors derived from the fungus Epicoccum nigrum, for treating diseases caused by excessive accumulation of sulfatides, such as metachromatic leukodystrophy (MLD). These compounds selectively inhibit the enzyme galactosylceramide-sulfotransferase, which is responsible for the synthesis of sulfatides that can accumulate and damage nervous system tissue. The invention also includes pharmaceutical formulations for delivering these inhibitors effectively, potentially overcoming difficulties seen with existing therapies like enzyme replacement and gene therapy.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of metachromatic leukodystrophy (MLD) in children and adults.
• Potential therapy for other sulfatide-accumulating diseases, including Krabbe disease, adrenoleukodystrophy, Pelizaeus-Merzbacher disease, Canavan disease, Alexander disease, Refsum disease, Vanishing White Matter Disease, and cerebrotendinous xanthomatosis.
• Use as a research tool to study demyelinating disorders or lysosomal storage diseases.
• Development of novel drugs targeting the central and peripheral nervous system pathologies caused by sulfatide accumulation.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel therapeutic approach that addresses the underlying metabolic defect in MLD and similar diseases by blocking sulfatide synthesis, rather than replacing missing enzymes.
• Small molecule inhibitors are more likely to cross the blood-brain barrier, enabling effective targeting of central nervous system diseases where other therapies struggle to penetrate.
• Reduces the need for invasive or complex procedures such as gene therapy, stem cell transplants, or repeated enzyme infusions.
• Potential for oral or injectable administration in user-friendly pharmaceutical compositions.
• May have broader applicability beyond MLD to other leukodystrophies and lysosomal storage disorders involving sulfatide accumulation.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention pertains to a novel treatment of pathologies caused by an increased synthesis or accumulation of sulfolipids such as sulfatide. The invention provides compounds isolated from Epicoccum nigrum strains 749 and 800, which were identified as inhibitors of Sulfotransferase, an enzyme catalyzing the generation of sulfatide. Sulfatides accumulate in the central nervous system (CNS) and lead to a degeneration of white matter. The present invention therefore preferably provides new therapeutic options for treating such diseases by administration of Epicoccum nigrum derived compounds. Further provided are pharmaceutical compositions comprising these compounds.